ASCO 2021 Prostate Cancer - Results from #60

Viewing 61-80 of 90 articles

ASC0 2021: Phase III study of local or systemic therapy INtensification DIrected by PET in prostate CAncer patients with post-prostaTEctomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191

ASCO 2021: Diagnostic Performance of Ga-68 PSMA PET/CT Imaging In Early-Relapsed Prostate Cancer: Phase 3, Prospective, Multicenter Study (IAEA-PSMA study)

ASCO 2021: The CADMUS Trial: Comparing mpMRI Ultrasound Targeted Biopsies With mpMRI Targeted Biopsies in the Detection of Clinically Significant Prostate Cancer

ASCO 2021: MRI and Targeted Biopsies Compared to Transperineal Mapping Biopsies For Targeted Ablation In Recurrent Prostate Cancer After Radiotherapy: The FORECAST Trial

ASCO 2021: Have We Optimized the Detection and Risk Stratification in Men With Localized Prostate Cancer?

ASCO 2021: Phase 1b Study of AMG 757, a Half-Life Extended Bispecific T-Cell Engager Targeting DLL3, in De Novo or Treatment Emergent Neuroendocrine Prostate Cancer

ASCO 2021: Darolutamide Tolerability from Extended Follow up and Treatment Response in the Phase 3 ARAMIS Trial

ASCO 2021: Real-World Treatment Patterns Among Patients Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) in Community Oncology Settings

ASCO 2021: Interim Results of AASUR: A Single Arm, Multi-Center Phase 2 Trial of Apalutamide + Abiraterone Acetate + Prednisone + Leuprolide With Stereotactic Ultra-Hypofractionated Radiation in Very High Risk, Node Negative Prostate Cancer

ASCO 2021: ODENZA: A French Prospective, Randomized, Open-Label, Multicenter, Cross-over Phase II Trial of Preference Between Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-Resistant Prostate Cancer

ASCO 2021: Is There a Role for Systemic Therapy Intensification With Radiotherapy in Locally Advanced Prostate Cancer?

ASCO 2021: TALAPRO-2: A Phase 3 Randomized Study of Enzalutamide plus Talazoparib Versus Placebo in Patients with New mCRPC

ASCO 2021: Interim PSMA PET/CT for Response Evaluation During LuPSMA Treatment in mCRPC (INTERIM PET): An Explorative, Multicenter Study

ASCO 2021: A Phase III Trial of Docetaxel Versus Docetaxel and Radium-223 in Patients With mCRPC: DORA

ASCO 2021: Radium-223 Versus Novel Antihormone Therapy for Progressive mCRPC After 1 Line of NAH: RADIANT, an International Phase 4, Randomized, Open-Label Study

ASCO 2021: Impact of Age on Efficacy and Safety of Relugolix: A Subgroup Analysis from the Randomized, Phase 3 HERO Study Versus Leuprolide in Men with Advanced Prostate Cancer

ASCO 2021 Science of Oncology Award and Lecture

ASCO 2021: Radiation and Androgen Deprivation Therapy with or Without Docetaxel in the Management of Non-Metastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial

ASCO 2021: Real-World Utilization of Advanced Therapies and Racial Disparity Among Patients with Metastatic Castration-Sensitive Prostate Cancer: A Medicare Database Analysis

ASCO 2021: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-Line Hormonal Treatment (SPLASH)

1
2
3
4
5

email news signup